New medical insurance reimbursement policy for Eltrombopag/Eltrombopag

The original drug of Eltrombopag/Eltrombopag has been launched in China and has been included in the medical insurance, and the reimbursement category is Category B of the medical insurance. However, the reimbursement ratio may be different in different regions, and the price after reimbursement may be somewhat different. Patients need to obtain a doctor's prescription before using eltrombopag. When purchasing drugs, patients need to go to a medical insurance designated pharmacy or hospital store and pay part of the cost out of pocket.

The current medical insurance reimbursement conditions for Eltrombopag ethanolamine tablets are currently limited to: 1) Adults and children aged 6 and above with chronic immune (idiopathic) thrombocytopenia (ITP) who have had poor response to glucocorticoids, immunoglobulins and other treatments in the past; 2) Patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive treatment in the past.

Eltrombopag’s new medical insurance reimbursement policy provides patients with certain financial support, but the specific reimbursement ratio and scope of application may vary depending on regions and medical insurance policies. As for price, the original drug of Eltrombopag currently sold in the domestic market is mainly available in two specifications: 25 mg 14 tablets and 25 mg 28 tablets. The price of each box is roughly between 2,000 and 4,000 yuan.

In overseas markets, the price of original drugs sold in places such as Turkey and India may be slightly lower, about more than 1,000 yuan per box ( prices may fluctuate due to exchange rates). In addition, generic versions of eltrombopag are also produced in places such as Bangladesh and Laos, and their prices may be more affordable, with each box selling for around a few hundred yuan (prices may fluctuate due to exchange rates).